Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine orodispersible fixed-dose study in outpatients with major depressive disorder
ISRCTN38378163Phase 2Completed
- Sponsor
- Servier
- Start
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (3 arms), sponsored by Servier. Primary endpoint: Hamilton Rating Scale for Depression (HAM-D). Started Feb 2008; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN38378163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38378163.